Carmat SAS, the French government-backed developer of a total artificial heart (TAH) for end-stage biventricular heart failure, has CE marked its device and plans to roll it out commercially in the first quarter of 2021, starting in Germany and Kazakhstan.
CE marking was granted on 22 December for the Carmat TAH system as a bridge to transplant in patients suffering...







